Conflict of interest None declared.
Infantile haemangiomas: a challenge in paediatric dermatology
Article first published online: 5 MAY 2010
© 2010 The Authors. Journal compilation © 2010 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 24, Issue 6, pages 631–638, June 2010
How to Cite
Schwartz, R., Sidor, M., Musumeci, M., Lin, R. and Micali, G. (2010), Infantile haemangiomas: a challenge in paediatric dermatology. Journal of the European Academy of Dermatology and Venereology, 24: 631–638. doi: 10.1111/j.1468-3083.2010.03650.x
- Issue published online: 5 MAY 2010
- Article first published online: 5 MAY 2010
- Received: 28 May 2007; Accepted: 27 December 2007
- vascular neoplasms
Infantile haemangiomas, common benign vascular tumours of childhood, are characterized by rapid growth during the first year of life and a slow regression that is usually completed at 7–10 years of age. These tumours are composed of endothelial cells with high mitotic rates and stromal components such as fibroblasts, mast cells and pericytes. Haemangiomas become a challenge when they are part of a syndrome, are located in certain areas of the body or when complications develop. The above-mentioned factors also influence the treatment modality used. However, although there remain many uncertainties regarding management, the β-adrenergic receptor blocker propranolol is a promising new candidate for first-line systemic therapy. It produces such a dramatic and rapid response that the appearance of an infantile haemangioma should impart expeditious consideration of the risks and benefits of its use.